SrasV1, PubMed, Curation, bibRecord, 001810

A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.

Identifieur interne : 001810 ( PubMed/Curation ); précédent : 001809; suivant : 001811

A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.

Auteurs : Craig W. Day [États-Unis] ; Ralph Baric ; Sui Xiong Cai ; Matt Frieman ; Yohichi Kumaki ; John D. Morrey ; Donald F. Smee ; Dale L. Barnard

Source :

Virology [ 1096-0341 ] ; 2009.

RBID : pubmed:19853271

Descripteurs français

KwdFr :
- Animaux, Antiviraux (pharmacologie), Cytokines (métabolisme), Femelle, Génome viral, Mutation, Poumon (anatomopathologie), Poumon (métabolisme), Protéines virales (génétique), Protéines virales (métabolisme), Régulation de l'expression des gènes (physiologie), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (métabolisme), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (physiologie).
MESH :
- anatomopathologie : Poumon.
- génétique : Protéines virales.
- métabolisme : Cytokines, Poumon, Protéines virales, Syndrome respiratoire aigu sévère.
- pharmacologie : Antiviraux.
- physiologie : Régulation de l'expression des gènes, Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Femelle, Génome viral, Mutation, Souris, Souris de lignée BALB C.

English descriptors

KwdEn :
- Animals, Antiviral Agents (pharmacology), Cytokines (metabolism), Female, Gene Expression Regulation (physiology), Genome, Viral, Lung (metabolism), Lung (pathology), Mice, Mice, Inbred BALB C, Mutation, SARS Virus (physiology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (metabolism), Severe Acute Respiratory Syndrome (virology), Viral Proteins (genetics), Viral Proteins (metabolism).
MESH :
- chemical , genetics : Viral Proteins.
- chemical , metabolism : Cytokines, Viral Proteins.
- chemical , pharmacology : Antiviral Agents.
- drug therapy : Severe Acute Respiratory Syndrome.
- metabolism : Lung, Severe Acute Respiratory Syndrome.
- pathology : Lung.
- physiology : Gene Expression Regulation, SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Female, Genome, Viral, Mice, Mice, Inbred BALB C, Mutation.

Abstract

Severe acute respiratory syndrome (SARS) is a highly lethal emerging disease caused by coronavirus SARS-CoV. New lethal animal models for SARS were needed to facilitate antiviral research. We adapted and characterized a new strain of SARS-CoV (strain v2163) that was highly lethal in 5- to 6-week-old BALB/c mice. It had nine mutations affecting 10 amino acid residues. Strain v2163 increased IL-1alpha, IL-6, MIP-1alpha, MCP-1, and RANTES in mice, and high IL-6 expression correlated with mortality. The infection largely mimicked human disease, but lung pathology lacked hyaline membrane formation. In vitro efficacy against v2163 was shown with known inhibitors of SARS-CoV replication. In v2163-infected mice, Ampligen was fully protective, stinging nettle lectin (UDA) was partially protective, ribavirin was disputable and possibly exacerbated disease, and EP128533 was inactive. Ribavirin, UDA, and Ampligen decreased IL-6 expression. Strain v2163 provided a valuable model for anti-SARS research.

DOI: 10.1016/j.virol.2009.09.023
PubMed: 19853271

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001810

Links to Exploration step

pubmed:19853271

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.</title>
<author><name sortKey="Day, Craig W" sort="Day, Craig W" uniqKey="Day C" first="Craig W" last="Day">Craig W. Day</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Antiviral Research, Utah State University, UMC 5600, Logan, UT 84322-5600, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Antiviral Research, Utah State University, UMC 5600, Logan, UT 84322-5600</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Baric, Ralph" sort="Baric, Ralph" uniqKey="Baric R" first="Ralph" last="Baric">Ralph Baric</name>
</author>
<author><name sortKey="Cai, Sui Xiong" sort="Cai, Sui Xiong" uniqKey="Cai S" first="Sui Xiong" last="Cai">Sui Xiong Cai</name>
</author>
<author><name sortKey="Frieman, Matt" sort="Frieman, Matt" uniqKey="Frieman M" first="Matt" last="Frieman">Matt Frieman</name>
</author>
<author><name sortKey="Kumaki, Yohichi" sort="Kumaki, Yohichi" uniqKey="Kumaki Y" first="Yohichi" last="Kumaki">Yohichi Kumaki</name>
</author>
<author><name sortKey="Morrey, John D" sort="Morrey, John D" uniqKey="Morrey J" first="John D" last="Morrey">John D. Morrey</name>
</author>
<author><name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F" last="Smee">Donald F. Smee</name>
</author>
<author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19853271</idno>
<idno type="pmid">19853271</idno>
<idno type="doi">10.1016/j.virol.2009.09.023</idno>
<idno type="wicri:Area/PubMed/Corpus">001810</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001810</idno>
<idno type="wicri:Area/PubMed/Curation">001810</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001810</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.</title>
<author><name sortKey="Day, Craig W" sort="Day, Craig W" uniqKey="Day C" first="Craig W" last="Day">Craig W. Day</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Antiviral Research, Utah State University, UMC 5600, Logan, UT 84322-5600, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Antiviral Research, Utah State University, UMC 5600, Logan, UT 84322-5600</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Baric, Ralph" sort="Baric, Ralph" uniqKey="Baric R" first="Ralph" last="Baric">Ralph Baric</name>
</author>
<author><name sortKey="Cai, Sui Xiong" sort="Cai, Sui Xiong" uniqKey="Cai S" first="Sui Xiong" last="Cai">Sui Xiong Cai</name>
</author>
<author><name sortKey="Frieman, Matt" sort="Frieman, Matt" uniqKey="Frieman M" first="Matt" last="Frieman">Matt Frieman</name>
</author>
<author><name sortKey="Kumaki, Yohichi" sort="Kumaki, Yohichi" uniqKey="Kumaki Y" first="Yohichi" last="Kumaki">Yohichi Kumaki</name>
</author>
<author><name sortKey="Morrey, John D" sort="Morrey, John D" uniqKey="Morrey J" first="John D" last="Morrey">John D. Morrey</name>
</author>
<author><name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F" last="Smee">Donald F. Smee</name>
</author>
<author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name>
</author>
</analytic>
<series><title level="j">Virology</title>
<idno type="eISSN">1096-0341</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Cytokines (metabolism)</term>
<term>Female</term>
<term>Gene Expression Regulation (physiology)</term>
<term>Genome, Viral</term>
<term>Lung (metabolism)</term>
<term>Lung (pathology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mutation</term>
<term>SARS Virus (physiology)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (metabolism)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Viral Proteins (genetics)</term>
<term>Viral Proteins (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cytokines (métabolisme)</term>
<term>Femelle</term>
<term>Génome viral</term>
<term>Mutation</term>
<term>Poumon (anatomopathologie)</term>
<term>Poumon (métabolisme)</term>
<term>Protéines virales (génétique)</term>
<term>Protéines virales (métabolisme)</term>
<term>Régulation de l'expression des gènes (physiologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère (métabolisme)</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines virales</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lung</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytokines</term>
<term>Poumon</term>
<term>Protéines virales</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Régulation de l'expression des gènes</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Gene Expression Regulation</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Genome, Viral</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mutation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Femelle</term>
<term>Génome viral</term>
<term>Mutation</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a highly lethal emerging disease caused by coronavirus SARS-CoV. New lethal animal models for SARS were needed to facilitate antiviral research. We adapted and characterized a new strain of SARS-CoV (strain v2163) that was highly lethal in 5- to 6-week-old BALB/c mice. It had nine mutations affecting 10 amino acid residues. Strain v2163 increased IL-1alpha, IL-6, MIP-1alpha, MCP-1, and RANTES in mice, and high IL-6 expression correlated with mortality. The infection largely mimicked human disease, but lung pathology lacked hyaline membrane formation. In vitro efficacy against v2163 was shown with known inhibitors of SARS-CoV replication. In v2163-infected mice, Ampligen was fully protective, stinging nettle lectin (UDA) was partially protective, ribavirin was disputable and possibly exacerbated disease, and EP128533 was inactive. Ribavirin, UDA, and Ampligen decreased IL-6 expression. Strain v2163 provided a valuable model for anti-SARS research.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19853271</PMID>
<DateCompleted><Year>2009</Year>
<Month>12</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0341</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>395</Volume>
<Issue>2</Issue>
<PubDate><Year>2009</Year>
<Month>Dec</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
<Title>Virology</Title>
<ISOAbbreviation>Virology</ISOAbbreviation>
</Journal>
<ArticleTitle>A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.</ArticleTitle>
<Pagination><MedlinePgn>210-22</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2009.09.023</ELocationID>
<Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a highly lethal emerging disease caused by coronavirus SARS-CoV. New lethal animal models for SARS were needed to facilitate antiviral research. We adapted and characterized a new strain of SARS-CoV (strain v2163) that was highly lethal in 5- to 6-week-old BALB/c mice. It had nine mutations affecting 10 amino acid residues. Strain v2163 increased IL-1alpha, IL-6, MIP-1alpha, MCP-1, and RANTES in mice, and high IL-6 expression correlated with mortality. The infection largely mimicked human disease, but lung pathology lacked hyaline membrane formation. In vitro efficacy against v2163 was shown with known inhibitors of SARS-CoV replication. In v2163-infected mice, Ampligen was fully protective, stinging nettle lectin (UDA) was partially protective, ribavirin was disputable and possibly exacerbated disease, and EP128533 was inactive. Ribavirin, UDA, and Ampligen decreased IL-6 expression. Strain v2163 provided a valuable model for anti-SARS research.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Day</LastName>
<ForeName>Craig W</ForeName>
<Initials>CW</Initials>
<AffiliationInfo><Affiliation>Institute for Antiviral Research, Utah State University, UMC 5600, Logan, UT 84322-5600, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Baric</LastName>
<ForeName>Ralph</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cai</LastName>
<ForeName>Sui Xiong</ForeName>
<Initials>SX</Initials>
</Author>
<Author ValidYN="Y"><LastName>Frieman</LastName>
<ForeName>Matt</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kumaki</LastName>
<ForeName>Yohichi</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Morrey</LastName>
<ForeName>John D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y"><LastName>Smee</LastName>
<ForeName>Donald F</ForeName>
<Initials>DF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Barnard</LastName>
<ForeName>Dale L</ForeName>
<Initials>DL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>5P01AI059443</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01AI15435</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P01 AI059443</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01 AI015435</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01-AI-15435</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01 AI030048</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01-A1-30048</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>10</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Virology</MedlineTA>
<NlmUniqueID>0110674</NlmUniqueID>
<ISSNLinking>0042-6822</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016679" MajorTopicYN="N">Genome, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year>
<Month>06</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2009</Year>
<Month>06</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>09</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>10</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>10</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>12</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19853271</ArticleId>
<ArticleId IdType="pii">S0042-6822(09)00583-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.virol.2009.09.023</ArticleId>
<ArticleId IdType="pmc">PMC2787736</ArticleId>
<ArticleId IdType="mid">NIHMS148457</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Am J Pathol. 2005 Aug;167(2):455-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16049331</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2006;17(5):275-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17176632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11585785</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pathol. 2004 Jun;203(2):622-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15141376</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2006 Nov 1;177(9):6301-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17056560</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Opin Ther Pat. 2009 Mar;19(3):357-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19449500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2008 Jun;82(11):5137-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18367528</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Immunol. 2008 Jul;8(7):559-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18575461</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2008 Jun 20;371(1):110-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18406349</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2007;18(1):1-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17354647</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15657466</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2004 Mar;15(2):101-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15185728</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2009 Nov;90(Pt 11):2686-2694</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19625461</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Trop Med Hyg. 2000 Jul-Aug;63(1-2):71-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11357999</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vet Pathol. 2008 Jul;45(4):551-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18587105</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2008 Jun;78(3):230-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18313150</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 1994 Oct;25(2):105-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7847873</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2008 Feb;82(3):1414-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18032498</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2007 Apr 15;178(8):5200-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17404303</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2001 Jul-Aug;7(4):675-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11585531</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 1994 Mar 24;368(6469):339-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8127368</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):101-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17451827</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2007 Sep;75(3):179-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17428553</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):293-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12892961</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Appl Microbiol. 1971 Nov;22(5):797-801</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4332040</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2005 Mar 1;191(5):746-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15688290</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Med Res Rev. 2000 Sep;20(5):323-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10934347</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2007 Oct;76(1):21-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17560666</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Trends Mol Med. 2003 Aug;9(8):325-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12928032</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19944-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19036930</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2006 Mar 1;193(5):685-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16453264</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Respir Res. 2005 May 11;6:42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15888207</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Mol Immunol. 2004 Jun;1(3):193-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16219167</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):13-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17374415</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FASEB J. 2004 Sep;18(12):1439-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15247147</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antimicrob Chemother. 2008 Sep;62(3):437-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18565970</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2003 Feb;47(2):777-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12543691</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):4-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17825937</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 1972 Aug 25;177(4050):705-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4340949</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Pathol. 2003 Aug;34(8):743-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14506633</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Biol. 1972 Oct 14;70(3):567-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5083149</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 1993 Jun;21(2):155-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7687840</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2006 Feb 9;49(3):1198-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16451084</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 1998 Oct;79 ( Pt 10):2381-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9780043</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Pathol. 2008 Jun;172(6):1625-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18467696</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Immunol. 2005 Dec;5(12):917-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16322745</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Med Chem. 2006;13(17):2003-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16842194</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Mar;10(3):489-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15109419</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Histopathology. 2004 Aug;45(2):119-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15279629</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Appl Environ Microbiol. 1976 Jan;31(1):35-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">182074</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2005 Jan 28;326(4):905-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15607755</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1992 Sep;36(9):1837-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1329629</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2007 Jan;3(1):e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17222058</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Infect Disord Drug Targets. 2007 Mar;7(1):29-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17346209</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Adv Exp Med Biol. 2006;581:463-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17037579</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Pathol. 2007 Feb;170(2):538-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17255322</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 May;79(9):5833-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15827197</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2006 Aug;71(1):53-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16621037</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Formos Med Assoc. 2005 Feb;104(2):75-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15765160</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2008 Aug;79(2):105-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18423639</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Trends Microbiol. 2006 Jul;14(7):299-303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16759866</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2008 Apr 25;374(1):151-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18234270</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Oct 30;425(6961):915</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14586458</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2004 Jan;48(1):267-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14693549</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 1993 Jan;20(1):57-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8384433</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Exp Immunol. 2004 Mar;135(3):467-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15008980</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2007 Jul;81(14):7410-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17507479</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1998 Mar;72(3):2496-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9499112</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Infect Disord Drug Targets. 2007 Mar;7(1):59-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17346212</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2007 Feb;81(4):1848-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17151094</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2004 Apr 1;189(7):1164-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15031783</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chin Med J (Engl). 2003 Jul;116(7):976-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12890365</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1973 Apr;70(4):1174-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4197928</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1773-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781536</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Infect Dis. 2004 Oct 1;39(7):1071-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15472864</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2004 Jan;15(1):15-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15074711</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Immunol. 2007;25:443-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17243893</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antimicrob Chemother. 2007 Oct;60(4):741-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17704516</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Int J Immunopharmacol. 1988;10(3):197-209</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3182149</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2004 Sep 15;173(6):4030-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15356152</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2008 Feb;82(4):1819-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18057240</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Opin Ther Pat. 2009 Apr;19(4):415-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19441924</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2008 Mar;82(5):2274-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18094188</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001810 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001810 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:19853271
   |texte=   A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:19853271" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.

A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki